Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aureon Labs Renames Prostate Px Test
For over four years, Post-Op Px has integrated tissue, clinical and molecular information to enable physicians and their patients to make more informed decisions about post-surgical, adjuvant therapies.
For over four years, Post-Op Px has integrated tissue, clinical and molecular information to enable physicians and their patients to make more informed decisions about post-surgical, adjuvant therapies.
Atacama Labs Oy has developed an oral drug delivery technology (called ‘pneumatic dry granulation’ or ‘PDG Technology. The technology is aimed at replacing existing solid dosage form development
Reportedly, AuroSource is expected to partner with pharma firms globally and cultivate opportunities to research, manufacture and develop compounds across the entire drug life cycle. Aurobindo said that
The study results also showed numerically lower rates of major and clinically relevant non-major bleeding in patients treated with apixaban compared with those treated with enoxaparin. The results
Hizentra, a once weekly immunoglobulin (Ig) replacement therapy, provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body. CSL Behring claimed
Menarini said that it is planning to launch other drugs shortly, notably in UK, Germany and Ireland. Thierry Poiraud, general manager of Menarini in France, said: “We are
Poniard said that the Phase 2 trial enrolled 32 men. The trial was designed to evaluate the efficacy and safety of intravenous Picoplatin (120mg/meter squared) administered every three
As per the terms of the agreement, Allergan is expected to grant to Bristol-Myers Squibb exclusive worldwide rights to develop, manufacture and commercialise AGN-209323 and backup compounds. The
In the Connection trial, Dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function. Dimebon was
GSK’s MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) candidate is currently being evaluated as an adjuvant treatment in melanoma biopsy specimens in the Phase III clinical study Derma. To be